Literature DB >> 34181108

18F-FDG PETCT and 68Ga-DOTA PETCT mismatch with in vivo histopathological characterization of low-grade neuroendocrine pancreatic tumor.

Marcello Moro Queiroz1, Carlos Diego Holanda Lopes2, Alessandra Corte Real Salgues2, Felipe de Galiza Barbosa3, Emerson Shigueaki Abe2, Thales Parenti Silveira4, Marcel Cerqueira Cesar Machado2, Fernanda Cunha Capareli2.   

Abstract

BACKGROUND: Pancreatic neuroendocrine tumor (PNET) is a subgroup of neuroendocrine tumor (NET) that has unique biology and natural history. The histological classification has a major role in the management of this pathology, but in recent years Gallium 68 dotatate (68Ga-DOTA) scanning is at the center of a discussion about how these imaging technologies can modify clinical management of neuroendocrine tumors and how their results are correlated to Ki67 index.
METHOD: We hereby describe a case of a patient that investigated an unspecific stable pancreatic nodule suspected of high-grade NET after evaluation with 68Ga-DOTATOC positron emission tomography-computed tomography (PETCT) and 18F-Fluorodeoxyglucose (18F-FDG) PETCT.
RESULTS: The images corroborate the hypothesis of high-grade NET based on the standard uptake value (SUV) described in both image exams (16.4 in 18FDG PETCT and 9.2 in 68Ga-DOTATOC PETCT). After surgery, the histopathological analyses revealed a localized grade 2 well-differentiated NET, Ki-67 of 4.7, glucose transport proteins 1 (GLUT1) negative by immunohistochemistry, evidencing a rare case of mismatch between the functional image and the in vivo characterization of the neoplasm.
CONCLUSION: Functional imaging of neuroendocrine tumors with different modalities of PETCT is a well-described strategy for evaluating PNET and can dictate conducts in some cases. However, histopathological analysis is crucial to confirm the grade and prognosis related to this disease.

Entities:  

Keywords:  68Ga-DOTA PETCT; In vivo; Low grade; Mismatch; Neuroendocrine; Pancreatic tumor

Year:  2021        PMID: 34181108     DOI: 10.1186/s41824-021-00103-4

Source DB:  PubMed          Journal:  Eur J Hybrid Imaging        ISSN: 2510-3636


  14 in total

1.  GLUT1 expression in tissue and (18)F-FDG uptake.

Authors:  Norbert Avril
Journal:  J Nucl Med       Date:  2004-06       Impact factor: 10.057

Review 2.  Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.

Authors:  Laura Evangelista; Ilaria Ravelli; Antonio Bignotto; Diego Cecchin; Pietro Zucchetta
Journal:  Clin Imaging       Date:  2020-06-09       Impact factor: 1.605

3.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

4.  PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.

Authors:  Melpomeni Fani; Luigi Del Pozzo; Keelara Abiraj; Rosalba Mansi; Maria Luisa Tamma; Renzo Cescato; Beatrice Waser; Wolfgang A Weber; Jean Claude Reubi; Helmut R Maecke
Journal:  J Nucl Med       Date:  2011-06-16       Impact factor: 10.057

5.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

6.  Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.

Authors:  Samer Ezziddin; Timur Logvinski; Charlotte Yong-Hing; Hojjat Ahmadzadehfar; Hans-Peter Fischer; Holger Palmedo; Jan Bucerius; Michael J Reinhardt; Hans-Jürgen Biersack
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

7.  Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.

Authors:  Levent Kabasakal; Emre Demirci; Meltem Ocak; Clemens Decristoforo; Ahmet Araman; Yıldız Ozsoy; Ilhami Uslu; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-20       Impact factor: 9.236

8.  Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging.

Authors:  Jin-Haeng Chung; Kyung-Ja Cho; Seung-Sook Lee; Hee Jong Baek; Jong-Ho Park; Gi Jeong Cheon; Chang-Woon Choi; Sang Moo Lim
Journal:  J Nucl Med       Date:  2004-06       Impact factor: 10.057

9.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

10.  Correlation between Standardized Uptake Value of 68Ga-DOTA-NOC Positron Emission Tomography/Computed Tomography and Pathological Classification of Neuroendocrine Tumors.

Authors:  Chalermrat Kaewput; Subapriya Suppiah; Sobhan Vinjamuri
Journal:  World J Nucl Med       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.